Live Breaking News & Updates on Bancroft Group

Stay updated with breaking news from Bancroft group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Cellphire Therapeutics Names Michael Gaffney as Company's New CEO


Cellphire Therapeutics Names Michael Gaffney as Company s New CEO
News provided by
Share this article
Share this article
ROCKVILLE, Md., April 20, 2021 /PRNewswire/  Cellphire Therapeutics, Inc., a biotechnology company developing next-generation platelet-based hemostatic therapeutics for application across multiple medical indications, announced today that Michael Gaffney has joined the company as Chief Executive Officer, effective immediately. Mr. Gaffney brings deep health sector insight, extensive operational experience, and proven strategy and capital markets expertise to Cellphire. He will also join the Company s board. 
We re thrilled to have Mike join the Cellphire team, said Tom Dubin, Executive Chairman. He joins us at an exciting time, as Cellphire begins two Phase 2 clinical trials with two distinct investigational products, Thrombosomes® and Cryopreserved Platelets. Mike s proven and steady leadership and his background in health care and c ....

Michael Gaffney , Tom Dubin , Biomedical Advanced Research , Human Services , Development Command Under Contract No , Us Army Medical Research , Development Authority , Department Of The Army , Bancroft Group , Cellphire Therapeutics Inc , Us Navy , Department Of Health , Office Of The , Oxford University , As Board Of Trustees , United States Naval Academy , Cellphire Therapeutics , Chief Executive Officer , Executive Chairman , Rhodes Scholar , Assistant Secretary , Medical Research , Development Command , மைக்கேல் காஃப்னி , டோம் டபின் , மனிதன் சேவைகள் ,